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Guidance for Pharmacists on the Safe Supply of Methadone  
 
1. Introduction  
The purpose of this guidance is to remind registered pharmacists involved in the supply of 
methadone, and the provision of associated services to patients, of the requirements which must be 
fulfilled in order to ensure compliance with legal and professional obligations.  
 
2. Methadone 
Methadone is a Schedule 2 controlled drug which is used in the treatment of opioid addiction as 
substitution or maintenance therapy, within a broader treatment protocol, accompanied by regular 
reviews and reassessment. This treatment must be supervised by specialist services. Certain 
methadone products are also licensed for the relief of severe pain in conditions where morphine 
may be a reasonable alternative, such as severe cancer pain.1 
  
3. Legal Considerations 
The principal legal requirements governing the supply of methadone and the provision of related 
services are contained in the Misuse of Drugs (Supervision of Prescription and Supply of Methadone) 
Regulations 1998 (S.I. No. 225 of 1998). It is an offence to supply methadone otherwise than in 
accordance with these regulations.  Pharmacists must also comply with the requirements of the 
Pharmacy Act 2007, the Regulation of Retail Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 
2008) and the Misuse of Drugs Acts and the orders and regulations made thereunder, including the 
Misuse of Drugs Regulations 1988 (S.I. No. 328 of 1988) (as amended).   
 
In addition, pharmacists must ensure their professional practice in relation to patients is in 
compliance with the Methadone Protocol2, the guidance of the PSI (as the statutory regulator) and 
the statutory Code of Conduct for pharmacists. 
 
4. Code of Conduct for Pharmacists 
Throughout the process of managing the supply of methadone and the provision of related 
services to patients, pharmacists must ensure that, in accordance with the first principle of the 
statutory Code of Conduct for pharmacists, the practice of their profession is directed toward 
maintaining and improving the health, wellbeing, care and safety of patients.  
 
                                                          
1
 The therapeutic indications are as per the Summaries of Product Characteristics for methadone products 
(available via the Irish Medicines Board website www.imb.ie). 
2
 The Methadone Protocol is the arrangements in place to implement and support the Misuse of Drugs 
(Supervision of Prescription and Supply of Methadone) Regulations 1998 (S.I. No. 225 of 1998). 
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Pharmacists should use their professional skills and competencies, and specialised knowledge, to 
encourage the rational and proper use of methadone and any other medicines the patient is taking. 
They should comply with all relevant laws, regulations and professional standards and ensure the 
patient is treated with courtesy, dignity, integrity and honesty. Pharmacists may be required to use 
their professional skills in decision-making, which may at times come into conflict with the demands 
of the patient. 
 
Pharmacists, in particular superintendent and supervising pharmacists, should ensure that suitable 
controls and accountability mechanisms are in place, in order to appropriately control the supply of 
methadone and all other medicinal products which are known to have the potential for abuse and/ 
or dependency. 
 
5. Guidance 
 
5.1 The Supply of Methadone for Opioid Dependence and the Provision of 
Associated Services to Patients 
 
5.1.1 Initiating Methadone Services 
Prior to commencing methadone treatment therapy services to patients, superintendent and 
supervising pharmacists must ensure that: 
 the pharmacy premises, including the patient consultation area (or area where the 
consultation will occur), are appropriate3  
 the pharmacy has all necessary equipment 
 the provision of the service is covered by appropriate professional indemnity arrangements, 
 there are adequate pharmacist staff available to allow for the appropriate supervision of all 
professional activities within the pharmacy and to fulfil all legal and professional 
requirements 
  relevant policies and procedures are in place to ensure robust clinical governance and  
 all pharmacists and other staff involved in providing the service are appropriately trained 
and competent to do so. 
 
Pharmacists wishing to commence methadone services should contact the relevant Health Service 
Executive (HSE) liaison pharmacist, who will notify the retail pharmacy business (pharmacy) if a 
suitable patient presents for treatment and provide the pharmacist with additional relevant 
information. Prior to commencing supply, a pharmacy is required to be authorised by HSE addiction 
services to receive methadone from a wholesaler. 
 
5.1.2 Registration of Patients 
Every patient must be registered on the Central Treatment List, prior to commencing treatment. 
Each patient is registered with one specific, appropriately trained General Practitioner (GP) and one 
specific pharmacy. On registration, every patient is issued with a unique PH number and the 
pharmacy is issued with a treatment card containing this number, the patient’s name, a photograph 
of the patient, a copy of the patient’s signature and the name of the patient’s GP and pharmacy. 
Cards are valid for a maximum of one year. They are the property of the pharmacy and should not 
be given to the patient. 
 
                                                          
3
 Refer to PSI Guidelines on Patient Consultation Areas in Retail Pharmacy Businesses and all other relevant 
information. 
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Pharmacists must ensure they only provide methadone services to patients registered to receive 
methadone from their pharmacy. Accordingly, all opioid dependent patients attending their 
pharmacy for methadone supplies must have a current valid drug treatment card. Pharmacists can 
check relevant information via the Central Treatment List (9am to 5pm, Monday to Friday, Phone: 01 
6488640). Drug Treatment Cards should be stored safely and confidentially, on the pharmacy 
premises, and should be available and accessible, for reference, to all pharmacists practising in the 
pharmacy.  
 
5.1.3 Medical Practitioners 
GPs must undergo specific training in order to provide methadone services to patients. There are 
two levels of training, level one and level two; level one GPs may only treat stabilised patients, 
whereas level two GPs may initiate treatment and can provide services to a greater number of 
opioid dependant patients. A GP’s level of training may be checked via the Central Treatment List. 
 
5.1.4 New Patients 
Prior to commencing the supply of methadone to an opioid-dependent patient, the supervising 
pharmacist should first satisfy himself/herself that the patient is a person in respect of whom a drug 
treatment card has been issued. The supervising pharmacist should then meet with the patient to 
discuss any issues the pharmacist or patient deems significant, including the patient’s privacy, 
patient and pharmacist expectations from the service, providing the patient with relevant 
information and associated counselling. The confidential nature of the service should be explained 
to patients. If the pharmacy only dispenses methadone to patients at particular times, these times 
should be clearly communicated. 
 
It is recommended that pharmacists put patient-pharmacy agreements in place regarding the 
parameters of the service. These agreements should be tailored to individual pharmacy 
requirements and specific patient needs. They should address the expectations of the patient and 
pharmacist, the risks associated with storing methadone incorrectly and with giving methadone to 
another person and all other items the pharmacist or patient may deem relevant.  
 
5.1.5 Methadone Prescriptions 
Methadone may only be supplied to a patient if it has been prescribed by their Methadone Protocol 
Scheme GP on the standard methadone prescription form. A copy of the methadone prescription 
form (as of November 2011) is appended to this guidance (Appendix 1). The prescription must 
comply with the prescription writing requirements for Schedule 2 controlled drugs, as provided for 
in regulation 13 of the Misuse of Drugs Regulations 1988 (S.I. No. 328 of 1988) (as amended). 
 
The doctor must specify the patient’s details including the PH number and the prescription details 
including the date, the preparation name, strength and form, the total amount of methadone 
prescribed in words and figures, the daily dose, details of the days on which methadone is to be 
dispensed and the days methadone is to be taken under the supervision of the pharmacist, along 
with the prescriber’s signature and details. Individual methadone prescriptions for methadone 
treatment therapy should not be for more than seven days (eight days in exceptional circumstances, 
for example, to cover bank holidays). 
 
Following the supply of methadone in instalments, each instalment should be entered on the 
prescription and when the full prescription has been dispensed, the total amount supplied must be 
entered in the controlled drugs register and the entry dated with the date of final supply. In 
addition, the pharmacist should stamp and sign the prescription which should also be signed by the 
patient following the final supply.  
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Methadone prescriptions must be forwarded to the HSE (this function is carried out by the HSE on 
behalf of the Minister for Health) no later than 14 days after the last day of the month in which the 
supply was completed. 
 
5.1.6 Storage of Methadone 
Methadone must be stored in a safe or cabinet which complies with the requirements of the Misuse 
of Drugs (Safe Custody) Regulations 1982 (S.I. No. 321 of 1982) (as amended). The safe must be of 
sufficient capacity to store all stock of methadone and other Schedule 2 and 3 controlled drugs. 
Access to the safe should be controlled by the pharmacist and only the pharmacist or a person 
operating under the pharmacist’s supervision should be permitted to access the safe. 
 
5.1.7 Supply of Methadone 
Pharmacists should be familiar with the Summary of Product Characteristics (SPC) for all methadone 
products they supply and copies should be readily accessible within the pharmacy. 
 
Pharmacists must be cognisant of their obligations under regulation 9 of the Regulation of Retail 
Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 2008). Prior to supplying methadone, a 
pharmacist should review the prescription, having regard to the pharmaceutical and therapeutic 
appropriateness of the medicine therapy, including screening for any potential drug therapy 
problems including interactions, incorrect dosage or duration of treatment and clinical abuse and/ or 
misuse. 
 
The directions of the prescribing practitioner should be followed when supplying methadone, 
including the dosing, supervision and instalment directions. Notwithstanding this, pharmacists must 
ensure any element of a prescription which is unclear or incorrect is clarified with the prescriber 
prior to its dispensing.  
 
The ingestion of methadone under supervision must occur on the pharmacy premises and must be 
supervised by the pharmacist. This supervision should take place in the pharmacy’s private patient 
consultation area (or another private designated area). In addition, the pharmacist should ascertain 
if the patient is fit to consume their dose and after consumption should ensure the patient has 
consumed their dose, either by talking to the patient or by offering the patient a drink of water.  
 
Pharmacists should be aware that manufacturer’s bottles contain an overage and ‘take-away’ doses 
of methadone should never be supplied in these bottles or other glass bottles. They should be 
packed in unbreakable plastic bottles, fitted with a child resistant cap. For certain patients, e.g. those 
whose dose has recently changed, individual doses are the safer option. If patients are provided with 
a bottle containing several doses, a measure should be given. The suitability of patients for 
multidose dispensing should be discussed with the prescribing GP, as appropriate. Patients should 
be informed of the importance of returning any remaining methadone to the pharmacy for safe 
disposal and should also be advised how to dispose of empty bottles safely.  
 
All doses should be measured and double checked prior to dispensing and all supplies must be 
appropriately labelled. 
 
Pharmacists should communicate any concerns about a patient to the prescriber, for example, if a 
patient misses a dose or if the patient appears to be under the influence of other drugs or alcohol. 
Pharmacists should be aware that if a patient has missed three or more doses their tolerance may be 
reduced and there is a risk of accidental overdose if the patient’s full dose is dispensed.  If the 
prescriber alters a dose a new prescription must be received which specifies the new dose. 
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5.1.8 Patient Counselling 
Pharmacists must ensure each patient has sufficient information and advice on the proper use and 
storage of the product, and must offer to discuss all matters that the pharmacist in their professional 
judgement deems significant, as per their legal and professional obligations under regulation 9 of 
the Regulation of Retail Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 2008).  
 
Patients should be provided, at a minimum, with general information about methadone, including 
directions of use, any common side effects, the action to be taken if a dose is missed, interactions 
with alcohol and other drugs, e.g. benzodiazepines, cautionary notices about driving or operating 
heavy machinery, methods for safe disposal and the danger of an opioid-intolerant person ingesting 
methadone. In addition, pharmacists should be cognisant of patients’ wider medical and healthcare 
needs and provide holistic pharmaceutical care to patients.  
 
Patients should be encouraged to attend the pharmacy at the same time each day and the 
pharmacist must be available and offer to discuss any relevant issues with the patient, at each 
dispensing.  Pharmacists should ensure that in instances where they are unable to provide services 
to a patient, they take reasonable action to ensure the services are provided and the patient’s care is 
not jeopardised. In such circumstances, the relevant HSE liaison pharmacist should be contacted so 
an alternative service can be provided.  
 
5.1.9 Multidisciplinary Patient Care 
The supervising pharmacist and any other relevant pharmacist should establish a relationship with 
patients’ medical practitioners and any other healthcare professionals involved in patients’ care and 
regularly communicate with and/or meet these healthcare professionals. These 
communications/meetings should be a forum to discuss patients’ care and treatment and any issues 
which the pharmacist or medical practitioner, in their professional judgement, deems appropriate. 
The primary aim should be to ensure patients receive an appropriate standard of care.  
 
Interdisciplinary communication and continuity of care are particularly important for patients 
transitioning between environments, for example, patients transferring between drug treatment 
centres, hospitals, prisons and the community.  
 
In addition, pharmacists should communicate relevant issues to their HSE liaison pharmacist and/ or 
GP coordinator, as appropriate. 
 
5.1.10 Vaccination 
All staff members providing services to opioid-dependant patients should be protected against 
Hepatitis B. The HSE’s free hepatitis screening and vaccination scheme is available to all staff 
providing services within the Methadone Protocol Scheme and the HSE addiction services should be 
contacted if further information on this scheme is required. 
 
6. Supplying Methadone to Medical Practitioners  
In certain circumstances, a medical practitioner may request a supply of methadone for 
administration to patients under his/her care. In such circumstances, they are required to provide a 
written requisition to the pharmacist, as per the requirements for supplying a Schedule 2 controlled 
drug to a practitioner. Article 12 of the Misuse of Drugs Regulations 1988 (as amended) specifies the 
format of the requisition to be provided in such circumstances. Methadone may only be supplied to 
a practitioner if it has been requisitioned on the standard methadone prescription form and, as with 
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methadone prescriptions, requisitions must be forwarded to the HSE no later than 14 days after the 
last day of the month in which the supply was completed. 
 
A pharmacist who supplies methadone on foot of a requisition must satisfy himself/herself, in so far 
as is possible, that the medication will be used appropriately, i.e. to treat patients under the 
practitioner’s care.  
 
7.  Policies, Procedures, Training and Records 
Superintendent and supervising pharmacists should ensure that there are written policies and 
procedures in place for all aspects of the sale and supply of methadone and the provision of 
associated services. All policies and procedures should comply with legislation, the Code of Conduct 
for pharmacists, the Methadone Protocol Scheme, this guidance and all other relevant guidance. 
There should be policies, procedures and/or protocols in place which address: 
 new patients attending the pharmacy 
 pharmacy-patient agreements 
 dispensing and supplying methadone, including the identification of patients, preparation of 
doses, double checking, supervision of consumption, patient records etc. 
 counselling patients 
 the disposal of waste, including clinical, sharp, medicinal product and confidential waste 
 maintaining confidentiality throughout the process  
 interdisciplinary issues, including multi-disciplinary reviews, routine interactions and the 
continuity of patient care  
 the management of the spillage of methadone and body fluids  
 minimising the risk of disease transmission, including Hepatitis B vaccination of pharmacy 
staff  
 
All relevant policies and procedures already in existence within the pharmacy, i.e. sourcing, storage, 
disposal4, controlled drug record keeping and patient consultation area procedures etc., should be 
reviewed and updated as appropriate to incorporate any additional requirements, and cross-
referenced with the methadone policies and procedures as necessary.  
 
In addition, pharmacies should have an error and incident management system for recording and 
addressing errors and/or near misses and for monitoring all incidents and complaints. The 
procedures in place should ensure open communication with patients and continuous quality 
improvement to reduce the likelihood of recurrence.  
 
Superintendent and supervising pharmacists should ensure all pharmacists practising in the 
pharmacy, including those providing infrequent or occasional cover, and all other relevant staff are 
trained in the pharmacy’s policies and procedures and training records should be maintained.  
 
Every pharmacy should maintain a contact list with the contact details for patients, medical 
practitioners, the HSE liaison pharmacist(s), the GP co-ordinator(s) and all other relevant contacts. 
 
All legislatively required records, including invoices, copies of prescriptions and the controlled drugs 
register must be retained for two years. The superintendent pharmacist may consider it appropriate 
to maintain records beyond a period of two years, as such records may be required for legal, 
insurance or other purposes at some time in the future. 
  
                                                          
4
 The requirements for sourcing, storing and disposing of Schedule 2 controlled drugs are set out in the PSI 
Guidelines on the Sourcing, Storage and Disposal of Medicinal Products within a Retail Pharmacy Business. 
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There should be a system in place whereby all pharmacists maintain a record of relevant information 
and interactions pertaining to opioid-dependant patients, including patient-pharmacy agreements 
and records of all inter-professional reviews and other contact with prescribers.  
 
Pharmacists should be familiar with all relevant legislation, PSI guidance and HSE guidance and 
should be familiar with, and trained in, the pharmacies policies and procedures. Pharmacists should 
also be familiar with the contents of the following reports and reviews: 
 Report of the Methadone Treatment Services Review Group 1997 (Department of Health 
and Children) 
 Review of the Methadone Treatment Protocol 2005 (Department of Health and Children) 
 The Introduction of the Opioid Treatment Protocol (External Review of the Methadone 
Treatment Protocol) 2010 (HSE) 
 
7.1 Enquiries  
Persons enquiring about treatment for drug addiction should be referred in the first instance to their 
GP or a drug treatment clinic.  In addition, addiction services employ outreach workers who are in 
contact with drug users in the community and can facilitate introduction to treatment, or patients 
can be referred to the HSE Drugs/ HIV Helpline or www.drugs.ie. Information on drug treatment 
clinics and outreach workers is available from HSE addiction services. 
 
8. Supply of Methadone in Hospitals 
The provisions of the Misuse of Drugs (Supervision of Prescription and Supply of Methadone) 
Regulations 1998 (S.I. No. 225 of 1998) do not apply to methadone prescriptions issued in a hospital 
for administration to a patient in the hospital or, in exceptional circumstances, for supply to a 
patient who has attended the hospital for the treatment of opioid dependence or as an inpatient 
who is opioid dependent. Pharmacists supplying methadone in hospitals must be cognisant of all 
other requirements which must still be fulfilled in order to ensure compliance with legal and 
professional obligations and should ensure appropriate arrangements are in place for patients 
continuing treatment who are transitioning back into primary care.  
 
9. Supply of Methadone other than for Opioid Dependence 
Methadone may be used for the relief of severe pain in conditions where morphine may be a 
reasonable alternative, such as severe cancer pain. Pharmacists should ensure they are familiar with 
the SPCs, including the licensed indications, for all methadone products they supply and copies 
should be readily accessible within the pharmacy. 
 
The provisions of the Misuse of Drugs Regulations 1988 (S.I. No. 328 of 1988) (as amended) and the 
Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 1998 (S.I. No. 
225 of 1998) still apply. Methadone must still be prescribed on the standard methadone prescription 
form and the pharmacy must be authorised by the Department of Health to receive methadone 
from a wholesaler. The form of methadone (liquid, capsules or injection) and the strength of the 
preparation to be dispensed must be stated and the prescription must comply with controlled drug 
prescription writing requirements. 
 
However, the requirement that a patient is on the Central Treatment List and has been issued a drug 
treatment card does not apply, provided the prescription is issued by a medical consultant, or by a 
registered medical practitioner, following initiation by a medical consultant, and the consultant’s 
name and address are included on the prescription. In addition, in these cases, methadone can be 
prescribed for up to one month, as the rule that individual methadone prescriptions should not be 
for more than seven days does not apply.  
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Some methadone products may be ‘exempt medicinal products’5 (i.e. unauthorised/unlicensed 
medicinal products), in which case, pharmacists must be cognisant of the need to fulfil the additional 
requirements relating to such medicinal products. 
 
Pharmacists should discuss patients’ care and treatment with all relevant health care professionals, 
e.g. medical practitioners or pharmacists in other care settings, both when treatment is initiated and 
at appropriate intervals thereafter. Such discussions should highlight any issues which the 
pharmacist in their professional judgement deems appropriate. The primary aim should be to ensure 
patients receive an appropriate standard of care at all times, including when transitioning between 
environments, for example, when transferring from a hospital to community setting. 
 
Pharmacists supplying methadone and providing services to patients should be sufficiently 
competent in the management of chronic severe pain, familiar with all relevant clinical information 
and aware of the potential for dependence, abuse or misuse. They should communicate all relevant 
information to patients, or their carers, as appropriate. 
 
All relevant legislation is available via the PSI website www.thePSI.ie or via www.irishstatutebook.ie. 
 
 
 
 
Pharmaceutical Society of Ireland 
December 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
5
 An ‘Exempt Medicinal Product’ is defined in the Medicinal Products (Control of Manufacture) Regulations 
2007 as a medicinal product to which paragraph 2 of Schedule 1 to the Medicinal Products (Control of Placing 
on the Market) Regulations 2007, or any equivalent legislation in any EEA State other than the State, applies.  
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